A61K 47/6425
The peptide or protein in the drug conjugate being a receptor
Official title: {the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell}
A61K47/6425 (The peptide or protein in the drug conjugate being a receptor) appears on 352 US grants and 538 published applications in this corpus.
Search patents in A61K- Granted patents
- 352
- Published applications
- 538
- Assignees
- 314
- Inventors
- 1,054
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 4 | 0 |
| 1993 | 2 | 0 |
| 1994 | 4 | 0 |
| 1995 | 6 | 0 |
| 1996 | 8 | 0 |
| 1997 | 8 | 0 |
| 1998 | 8 | 0 |
| 1999 | 11 | 0 |
| 2000 | 18 | 0 |
| 2001 | 14 | 0 |
| 2002 | 5 | 18 |
| 2003 | 7 | 26 |
| 2004 | 9 | 21 |
| 2005 | 8 | 21 |
| 2006 | 5 | 26 |
| 2007 | 8 | 7 |
| 2008 | 4 | 12 |
| 2009 | 9 | 17 |
| 2010 | 9 | 17 |
| 2011 | 4 | 16 |
| 2012 | 9 | 10 |
| 2013 | 8 | 9 |
| 2014 | 8 | 11 |
| 2015 | 7 | 12 |
| 2016 | 9 | 13 |
| 2017 | 8 | 16 |
| 2018 | 7 | 28 |
| 2019 | 14 | 31 |
| 2020 | 16 | 29 |
| 2021 | 21 | 28 |
| 2022 | 18 | 35 |
| 2023 | 10 | 46 |
| 2024 | 22 | 31 |
| 2025 | 25 | 33 |
| 2026 | 19 | 25 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Bifunctional molecules for lysosomal targeting and related compositions and methods6 Oct 2026US 12,753,239 B2The Board of Trustees of the Leland Stanford Junior University
- Treatment of immunosuppressed subjects15 Sep 2026US 12,734,216 B2NantCell, Inc.
- Cobalt-doped iron oxide nanoparticles and methods for making and using1 Sep 2026US 12,721,907 B2Oregon Health & Science University
- Engineered immune-mobilizing T-cell receptors with enhanced affinity for HIV-1 gag4 Aug 2026US 12,698,316 B2Immunocore Limited
- Drug-controlled systems and uses thereof28 Jul 2026US 12,691,096 B2Trustees of Boston University
- Multi-target drug conjugate and use thereof for cancer treatment1 Oct 2026US 2026/0295061 A1Virginia Tech Intellectual Properties, Inc.
- Il-15-based molecules and methods of use thereof3 Sep 2026US 2026/0256886 A1Altor BioScience Corporation
- Agonistic interleukin 15 complexes and uses thereof20 Aug 2026US 2026/0242444 A1Suzhou Forlong Biotechnology Co., Ltd.
- T cell receptor13 Aug 2026US 2026/0232800 A1Adaptimmune Limited
- Novel immunoconjugates13 Aug 2026US 2026/0232829 A1Cytospire Therapeutics Limited
Most cited
By later US patents
- Ligands to enhance cellular uptake of biomolecules261US 5,994,517 A1999
- CD4 adheson variants230US 5,336,603 AGenentech, Inc. · 1994
- Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins194US 5,977,307 AAlkermes, Inc. · 1999
- Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use167US 7,262,177 B2Cell Works Therapeutics, Inc. · 2007
- Transferrin neuropharmaceutical agent fusion protein150US 5,672,683 AAlkermes, Inc. · 1997